GlassScriptPhysician profile
Lula D Thomas
NPI 1245668177
$6,984.47
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,056 · 2022: $2,436 · 2023: $2,025 · 2024: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,491.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.94 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $945.10 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $743.23 | 2021-2023 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $673.30 | 2021-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $581.64 | 2021-2023 | Uzedy, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $441.50 | 2021-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $434.30 | 2021-2023 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $395.75 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $309.14 | 2021-2023 | Qelbree |
| Lundbeck LLC | $280.00 | 2021-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $201.19 | 2021-2023 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $151.96 | 2022-2023 | Auvelity |
| Corium, LLC | $124.89 | 2022-2023 | Azstarys |
| Almatica Pharma LLC | $105.84 | 2022-2023 | Loreev Xr |
| Bausch Health US, LLC | $102.12 | 2021-2023 | Wellbutrin, Aplenzin |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $89.35 | 2021-2023 | Belsomra |
| Noven Therapeutics, LLC | $78.92 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $73.55 | 2022-2023 | Quviviq |
| Eisai INC. | $67.50 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $38.13 | 2022 | |
| Neos Therapeutics, LP | $31.61 | 2023 | Adzenys Xr-Odt |
| Indivior INC. | $23.03 | 2022 | |
| Noven Pharmaceuticals, INC. | $23.02 | 2022 | |
| Owp Pharmaceuticals, INC. | $16.41 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.79 | 2022 | |
| Allergan, INC. | $13.55 | 2021 | |
| Alfasigma USA, INC. | $12.88 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lula Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.